Clinical trials: Genital Neoplasms, Male
Prostate Cancer
Response of Patients on Surveillance for Prostate Cancer to Dutasteride
Hypothesis: That, in men on surveillance for favorable risk prostate cancer treated with dutasteride, prostate specific antigen (PSA) kinetics is of value in identifying those men who harbor occult high grade prostate cancer.
- Trial name
- NCT01525914
- Testing
- Dutasteride
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer Metastatic
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide…
- Trial name
- mCRPC (NCT03888612)
- Testing
- ARV-110
- Where
- 54 sites in United States
- Volunteers
- 248 people
- Sponsor
- Arvinas Inc.
Prostatic Neoplasms, Prostate Cancer
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
- Trial name
- NCT00383487
- Testing
- Calcitriol, Naproxen-n-butyl nitrate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving…
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07466498
- Testing
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostatic Neoplasm
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor…
- Trial name
- ODYSSEY (NCT00174863)
- Testing
- SR31747A
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 232 people
- Sponsor
- Sanofi
Prostatic Neoplasms
Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations
Radical prostatectomy has become the gold standard treatment for prostate cancer. Regarding of morbidity of access on open retropubic radical prostatectomy a lot of centers around the world start to develop laparoscopic and…
- Trial name
- ORP-SAC (NCT01955863)
- Testing
- patient discharge on postoperative day 2, patient discharge on postoperative day 1, patient discharge in the day of surgery
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Wesley Justino Magnabosco
Prostate Cancer
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00348816
- Testing
- docetaxel, prednisone, Radical prostatectomy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone…
- Trial name
- NCT00193193
- Testing
- Paclitaxel, Estramustine, Carboplatin
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Cervical Cancer
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
This Cancer Prevention and Treatment Demonstration Project funded by the Centers of Medicare and Medicaid Services awarded six sites across the United States to develop Patient Navigator Programs to eliminate disparities in the…
- Conditions
- Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT00379782
- Testing
- Navigation
- Where
- United States
- Volunteers
- 628 people, healthy volunteers welcome
- Sponsor
- Queen's Medical Center
Prostate Cancer
Continuous Monitoring of Prostate Position During Radiotherapy
This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating).
- Trial name
- KIM Gating (NCT01742403)
- Testing
- R/T gating kV intrafraction monitoring
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Royal North Shore Hospital
Prostate Cancer, Cancer Recurrence
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
- Trial name
- PERYTON (NCT04642027)
- Testing
- Conventional sEBRT, Hypofractionated sEBRT
- Where
- 13 sites in Netherlands
- Volunteers
- 538 people
- Sponsor
- University Medical Center Groningen
Prostatic Cancer, Castration-Resistant
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- DaroAcT (NCT04157088)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Prostate Cancer
bpMRI and Risk Based Shared Clinical Decision Making in Prostate Cancer Diagnosis
The shortcoming of the pre-biopsy prostate MRI approach is the recommendation to biopsy all men post-MRI even if there is no lesion seen in MRI, ie. risk of PCa is very low.
- Trial name
- multiIMPROD2 (NCT04287088)
- Testing
- A shared decision making
- Where
- 4 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Turku University Hospital
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer
Objective: The objective of this study is test the hypothesis that delivering a higher percentage of the radiation dose as external radiation versus implant will lead to higher tumor control rates.
- Trial name
- NCT00494546
- Testing
- Pd-103 with 20 vs 44 Gy supplemental beam XRT
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- VA Puget Sound Health Care System
Urinary Bladder Neoplasms, Prostatic Neoplasms
Lymphedema After Urologic Surgery
Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic…
- Conditions
- Urinary Bladder Neoplasms, Prostatic Neoplasms, Testicular Neoplasms, Penile Cancer
- Trial name
- NCT05264337
- Testing
- Self-reported lymphedema, Dielectric constant ratio, Limb volume
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Vastra Gotaland Region
Prostate Cancer
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
This will be a Phase II study evaluating the effectiveness and toxicity of a specific radiation therapy regimen. This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated…
- Trial name
- NCT00809991
- Testing
- hypofractionation
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007
The BioProtect Balloon Implant™ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the balloon to…
- Trial name
- NCT03400150
- Testing
- balloon, Control
- Where
- 16 sites in United States, Israel and 4 more
- Volunteers
- 222 people
- Sponsor
- BioProtect
Hot Flashes, Prostate Cancer
Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
RATIONALE: Gabapentin may be effective in relieving hot flashes in men who have prostate cancer. It is not yet known which regimen of gabapentin is most effective in treating hot flashes.
- Trial name
- NCT00028574
- Testing
- gabapentin
- Where
- 170 sites in United States
- Volunteers
- 223 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.